CN113088465A - 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 - Google Patents
一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 Download PDFInfo
- Publication number
- CN113088465A CN113088465A CN202110362172.3A CN202110362172A CN113088465A CN 113088465 A CN113088465 A CN 113088465A CN 202110362172 A CN202110362172 A CN 202110362172A CN 113088465 A CN113088465 A CN 113088465A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- health
- bifidobacterium lactis
- strain
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 62
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 62
- 239000003814 drug Substances 0.000 claims abstract description 36
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 28
- 239000006041 probiotic Substances 0.000 claims abstract description 24
- 235000018291 probiotics Nutrition 0.000 claims abstract description 24
- 238000004321 preservation Methods 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 230000000529 probiotic effect Effects 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 230000000968 intestinal effect Effects 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 20
- 235000013402 health food Nutrition 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 17
- 241000186000 Bifidobacterium Species 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 206010010774 Constipation Diseases 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 241000186660 Lactobacillus Species 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 9
- 208000028774 intestinal disease Diseases 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000193171 Clostridium butyricum Species 0.000 claims description 6
- 241000792859 Enema Species 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 239000002518 antifoaming agent Substances 0.000 claims description 6
- 239000003086 colorant Substances 0.000 claims description 6
- 239000007920 enema Substances 0.000 claims description 6
- 229940095399 enema Drugs 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013373 food additive Nutrition 0.000 claims description 6
- 239000002778 food additive Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- -1 glidants Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- 239000006189 buccal tablet Substances 0.000 claims description 5
- 230000001079 digestive effect Effects 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 241000186361 Actinobacteria <class> Species 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 3
- 241000194031 Enterococcus faecium Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 230000000181 anti-adherent effect Effects 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000007844 bleaching agent Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000005538 encapsulation Methods 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000834 fixative Substances 0.000 claims description 3
- 239000008394 flocculating agent Substances 0.000 claims description 3
- 239000004088 foaming agent Substances 0.000 claims description 3
- 235000010855 food raising agent Nutrition 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 230000007413 intestinal health Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000003380 propellant Substances 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229960001296 zinc oxide Drugs 0.000 claims description 3
- 235000014692 zinc oxide Nutrition 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 9
- 241000588724 Escherichia coli Species 0.000 abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 229940088710 antibiotic agent Drugs 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 3
- 241000607142 Salmonella Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 11
- 206010018910 Haemolysis Diseases 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- YLZYSVYZMDJYOT-UHFFFAOYSA-N 2-methoxypyrimidine Chemical compound COC1=NC=CC=N1 YLZYSVYZMDJYOT-UHFFFAOYSA-N 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 239000006781 columbia blood agar Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- XFIKMPRBSORKQP-JATHGWPISA-M lithium;9-[(e)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[[(2s,3s)-3-[(2s,3s)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoate Chemical class [Li+].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 XFIKMPRBSORKQP-JATHGWPISA-M 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明“一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用”属于微生物技术领域。所述乳双歧杆菌Bifidobacterium lactis菌株J605的保藏号为CGMCC No.21751,该菌株J605具有良好的肠道益生功能,较高的抗胃肠道胁迫的能力,对大肠杆菌、金黄色葡萄球菌、沙门氏菌具有明显的抑制作用及,对常见抗生素均具有敏感性,可广泛应用于改善肠道环境的药物、保健食品或饮品中,市场应用价值高。
Description
技术领域
本发明属于微生物技术领域,尤其是涉及一种乳双歧杆菌Bifidobacteriumlactis菌株J605及其应用。
背景技术
伴随着社会节奏的加快,生活水平的提高,人们的饮食结构也发生了很大改变,便秘的发生率也越来越大。慢性便秘是全球范围内常见的胃肠道功能紊乱症状,还可能引发其他疾病。同时,慢性便秘发生率的提高,严重影响人们的生活质量。影响慢性便秘的因素很多,如年龄、饮食习惯、生活方式等,其中年龄是影响便秘的一大因素。随着年龄的增长,肠道中有益菌数量逐渐减少,加上机体各项功能器官的退化,老年人慢性便秘的比重越来越大。然而,目前人们对慢性便秘的重视度不高,缺乏科学认识,同时滥用各种药物,导致慢性便秘反复延伸。
现有技术中,“药食同源”的概念在很多品牌中得以使用,将益生菌与多种药食同源食材混合使用,制成具有润肠通便的特殊药物。其中,益生菌多为双歧杆菌、乳酸杆菌等肠道益生菌株,药食同源食材多为何首乌、郁李仁等中药药物。但目前很多中药药物药理性不明,故该特殊膳食一般建议婴幼儿、老人、孕妇等人群慎用。
乳双歧杆菌是存在于人体肠道中的一种重要的益生菌群,对促进人体健康、调节机体免疫功能等方面具有重要意义。乳双歧杆菌在人体肠道定殖后能有效拮抗肠道病原菌,调节肠道菌群,促进肠道蠕动,从而改善肠道环境,缓解便秘。乳双歧杆菌的安全性比较高,生产成本相对较低,其工业化应用和推广具有广阔前景。
因此本领域亟需开发筛选更多有用的乳双歧杆菌。目前对多种病原菌有抑制作用、对多种抗生素敏感且对多种益生菌群有调节作用的乳双歧杆菌,本领域尚未见报道。
发明内容
针对本领域存在的上述需求与空白,本发明的目的在于提供一种具有益生特性的乳双歧杆菌及其应用,该菌具有较强的耐受性,并能调节肠道菌群,润肠通便。
本发明的目的通过下述技术方案实现:
一种乳双歧杆菌Bifidobacterium lactis菌株J605,其特征在于,其保藏号为CGMCC No.21751。
保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605在制备药物或食品方面的应用。
所述药物选自防治消化道病症的药物,优选防治肠道疾病的药物;
优选地,所述食品选自可改善肠道环境的保健食品;
优选地,所述药物的剂型选自:口服液、片剂、粉剂、颗粒剂、胶囊剂、灌肠剂、灌胃剂;
优选地,所述保健食品选自:饮品、含片、固体饮料;
一种防治消化道病症的药物,其特征在于,包括药效活性成分;所述药效活性成分包括保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605。
所述药效活性成分还包括其它常规益生菌;所述其它常规益生菌选自:屎肠球菌、双歧杆菌、粪肠球菌、乳酸杆菌,芽孢杆菌、酪酸梭菌。
所述的一种防治消化道病症的药物还包括药学上可接受的辅料;
优选地,所述药学上可接受的辅料选自:溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂、释放阻滞剂。
药物剂型选自:口服液、片剂、粉剂、颗粒剂、胶囊剂、灌肠剂、灌胃剂;
优选地,所述药物还包括菌的培养基;所述菌的培养基选自:维生素、乳糖、甘露醇、烟酰胺、乳酸钙、氧化锌、蛋白质、淀粉、水;
优选地,所述防治消化道病症指防治肠道疾病;更优选地,所述防治肠道疾病包括:防治腹泻、便秘、肠炎、肠道菌群失调、肠道消化功能障碍。
一种保健食品,其特征在于,包括保健活性成分;所述保健活性成分包括保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605。
所述的一种保健食品的保健活性成分还包括其它益生菌;所述其它益生菌选自:酵母菌、益生芽孢菌、丁酸梭菌、乳酸杆菌、双歧杆菌、放线菌;
优选地,所述保健食品还包括食品添加剂;
优选地,所述食品添加剂选自:酸度调节剂、抗结剂、消泡剂、抗氧化剂、漂白剂、膨松剂、着色剂、护色剂、酶制剂、增味剂、营养强化剂、防腐剂、甜味剂、增稠剂、香料。
所述保健食品选自:饮品、含片、咀嚼片、固体饮料;
所述保健指肠道保健;所述肠道保健指:改善肠道环境、调节肠道菌群。
本发明提供一种乳双歧杆菌(Bifidobacterium lactis)J605,其分类命名为Bifidobacterium lactis,该菌株已于2021年1月28日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.21751。所述的乳双歧杆菌的菌落形态为不透明乳白色,圆形有光泽,边缘整齐,表面凸起且湿润。所述的乳双歧杆菌对氧气较为敏感,为严格厌氧菌,培养时要置换空气为无氧空气。所述的乳双歧杆菌最适生长温度为37℃,最适初始pH值6.8。
所述的乳双歧杆菌具有如下体外益生功效:通过体外模拟人工胃液和人工肠液的耐受性评估结果表明,乳双歧杆菌J605在pH2.5的人工胃液中的3h存活率为91.20%,在pH8.0的人工肠液中的3h存活率为93.28%;对大肠杆菌、金黄色葡萄球菌、伤寒沙门氏菌的抑菌圈直径分别为34mm、27mm、26mm;对红霉素、青霉素、阿莫西林、氨苄西林、四环素、环丙沙星、万古霉素、头孢克洛、苯唑西林、头孢曲松、新生霉素、头孢噻吩、克林霉素、阿奇霉素、甲氧嘧啶、利福平的耐药性直径分别为46mm、43mm、11mm、45mm、38mm、21mm、19mm、27mm、40mm、25mm、35mm、21mm、30mm、39mm、29mm、40mm、32mm。
本发明的具有益生特性的乳双歧杆菌可应用于改善肠道环境的药物、健康食品或饮品中。
本发明的有益效果为:本发明的乳双歧杆菌J605具有良好的肠道益生作用,其具有较高的抗胃肠道胁迫的能力;对大肠杆菌、金黄色葡萄球菌、伤寒沙门氏菌具有明显的抑制作用;对红霉素、卡那霉素、链霉素、青霉素、头孢克肟、阿莫西林、氨苄西林、四环素、庆大霉素、环丙沙星、万古霉素、头孢克洛、苯唑西林、头孢曲松、新生霉素、新霉素、头孢噻吩、克林霉素、阿奇霉素、甲氧嘧啶、利福平等常见抗生素均具有敏感性。此外,用本发明的乳双歧杆菌具有良好的肠道益生功能,较高的抗胃肠道胁迫的能力及对各种抗生素都有一定程度的敏感性,可广泛应用于改善肠道环境的保健食品或饮品中,市场应用价值高。
本发明的乳双歧杆菌Bifidobacterium lactis菌株J605的保藏信息如下:
命名:J605
分类名称:乳双歧杆菌
拉丁名称:Bifidobacterium lactis
保藏号:CGMCC No.21751
保藏机构:中国微生物菌种保藏管理委员会普通微生物中心
保藏地址:北京市朝阳区北辰西路1号院3号
保藏日期:2021年1月28日
是否存活:是
具体实施方式
为详细说明本技术方案的技术内容、所实现的目的及效果,下面结合具体实施例进行详细描述,但并不以此限制本发明的保护范围。
下述实验例中所使用的实验方法如无特殊说明,均为常规方法。下述实验例中所采用的材料、试剂等,如无特殊说明,均可通过商业途径获取。
生物材料的来源
实验例4中用到的大肠杆菌、金黄色葡萄球菌、伤寒沙门氏菌均可商购获得;
实验例8中使用的BALB/c雄性小鼠可商购获得。
第1组实施例、本发明的乳双歧杆菌Bifidobacterium lactis菌株J605
本组实施例提供一种乳双歧杆菌Bifidobacterium lactis菌株J605,其保藏号为CGMCC No.21751。
基于本组实施例提供的菌株J605以及本发明说明书记载的内容,根据本发明的启示,本领域技术人员可将菌株J605用于多种工业生产或医疗保健用途,例如,可将菌株J605用来制备食品或药物,也可直接使用该菌株J605对人或动物进行治疗或保健。任何使用、生产、销售、许诺销售菌株J605的行为均落入本发明的保护范围。
第2组实施例、本发明的菌株J605的应用
本组实施例提供保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacteriumlactis菌株J605在制备药物或食品方面的应用。
在一些实施例中,所述药物选自防治消化道病症的药物,优选防治肠道疾病的药物;
优选地,所述食品选自可改善肠道环境的保健食品;
优选地,所述药物的剂型选自:口服液、片剂、粉剂、颗粒剂、胶囊剂、灌肠剂、灌胃剂;
优选地,所述保健食品选自:饮品、含片、固体饮料、胶囊、颗粒剂和滴剂等。
第3组实施例、本发明的防治消化道病症的药物
本组实施例提供一种防治消化道病症的药物。本组所有的实施例都具备如下共同特征:所述防治消化道病症的药物包括药效活性成分;所述药效活性成分包括根保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605。
在进一步的实施例中,所述药效活性成分还包括其它常规益生菌;所述其它常规益生菌选自:屎肠球菌、双歧杆菌、粪肠球菌、乳酸杆菌,芽孢杆菌、酪酸梭菌。
更具体地,芽孢杆菌包括枯草芽孢杆菌、地衣芽孢杆菌和凝结芽孢杆菌等;
更具体地,乳酸杆菌包括嗜酸乳杆菌、植物乳杆菌和鼠李糖乳杆菌等;
更具体地,双歧杆菌包括长双歧杆菌、短双歧杆菌和两歧双歧杆菌等;
在更进一步的实施例中,所述的一种防治消化道病症的药物还包括药学上可接受的辅料;
在优选的实施例中,所述药学上可接受的辅料选自:溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂、释放阻滞剂。
根据不同的药物剂型及制备工艺选择合适的药用辅料是本领域技术人员可根据本领域的技术常识可常规操作并实现的。
在一些实施例中,药物剂型选自:口服液、片剂、粉剂、颗粒剂、胶囊剂、灌肠剂、灌胃剂;
优选地,所述药物还包括菌的培养基;所述菌的培养基选自:维生素、乳糖、甘露醇、烟酰胺、乳酸钙、氧化锌、蛋白质、淀粉、水;
优选地,所述防治消化道病症指防治肠道疾病;更优选地,所述防治肠道疾病包括:防治腹泻、便秘、肠炎、肠道菌群失调、肠道消化功能障碍、肠易激综合征。
第4组实施例、本发明的保健食品
本组实施例提供一种保健食品,其特征在于,包括保健活性成分;所述保健活性成分包括保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605。
在进一步的实施例中,所述的一种保健食品的保健活性成分还包括其它益生菌;所述其它益生菌选自:酵母菌、益生芽孢菌、丁酸梭菌、乳杆菌、双歧杆菌、放线菌;
在更进一步的实施例中,所述保健食品还包括食品添加剂;
优选地,所述食品添加剂选自:酸度调节剂、抗结剂、消泡剂、抗氧化剂、漂白剂、膨松剂、着色剂、护色剂、酶制剂、增味剂、营养强化剂、防腐剂、甜味剂、增稠剂、香料。
在一些具体的实施例中,所述保健食品选自:饮品、含片、咀嚼片、固体饮料、胶囊、颗粒剂和滴剂等;
所述保健指肠道保健;所述肠道保健指:改善肠道环境、调节肠道菌群。
实验例1、本发明菌株J605的分离筛选
(1)样品采集
0~1岁健康的婴儿粪便样品,三个月内未服用过抗生素药物,纯母乳喂养。
(2)菌株分离
取1g样品放入9mL生理盐水中震荡混匀,菌悬液进行梯度稀释后,吸取适宜梯度菌液100μL于添加有莫匹罗星锂盐的双歧杆菌分离培养基琼脂平板上,均匀涂布,置换空气为无氧空气后37℃静置恒温培养48h。待菌落长出,挑取不透明乳白色,圆形有光泽,边缘整齐,表面凸起且湿润的单菌落,在MRS固体培养基上进行反复划线纯化培养,获得1株婴儿粪便细菌菌株,并在4℃下保存待用。
双歧杆菌分离培养基(g/L):牛肉膏10、蛋白胨10、酵母提取物5、葡萄糖20、乙酸钠5、柠檬酸氢二铵2、Tween 80 1、K2HPO4 2、MgSO4·7H2O 0.58、MnSO4·H2O 0.25,L-半胱氨酸氨酸盐0.5,118℃灭菌20min,MRS固体培养基加入1.5%的琼脂粉,琼脂化学结构稳定,在培养基中仅起凝固剂的作用,其在100℃时融化成液体,冷却到45℃以下即重新凝固。
所述菌株的菌落形态为不透明乳白色,圆形有光泽,边缘整齐,表面凸起且湿润。该菌株对氧气较为敏感,为严格厌氧菌,培养时要置换空气为无氧空气。该菌株最适生长温度为37℃,最适初始pH值6.8。
实验例2、本发明菌株J605的分子生物学鉴定
将初筛菌体纯化培养后收集,采用基因组DNA抽提试剂盒(TIANGEN公司)提取菌株基因组DNA,采用上游引物27F:AGTTTGATCMTGGCTCAG(SEQ ID NO.1)和下游引物1492R:GGTTACCTTGTTACGACTT(SEQ ID NO.2),对16S rDNA序列进行扩增,得到PCR产物。并对PCR产物进行测序。其中PCR反应体系:10×Buffer 5μL,引物dNTP 4μL,上、下游引物各2μL,DNA模板2μL,Taq酶0.5μL,ddH2O 34.5μL。PCR反应条件:95℃10min;94℃30s,56℃30s,72℃2min,35个循环;72℃10min。将PCR产物通过凝胶电泳检测后送往武汉金开瑞生物工程有限公司测序。将测得基因序列提交至NCBI数据库(www.ncbi.nlm.nih.gov)中进行BLAST分析比对,以16S rDNA基因序列同源性≥99%为鉴定标准。
经过上述鉴定,结果发现该菌株16S rDNA基因序列与Bifidobacterium lactis这类菌的同源性在99%以上,本发明将该菌株命名为J605,并送保藏,其保藏信息如下:
命名:J605
分类名称:乳双歧杆菌
拉丁名称:Bifidobacterium lactis
保藏号:CGMCC No.21751
保藏机构:中国微生物菌种保藏管理委员会普通微生物中心
保藏日期:2021年1月28日。
实验例3、乳双歧杆菌J605对模拟人工胃液和人工肠液的耐受性评价
取测试菌液100μL接种于装有7mL MRS液体培养基的充氮厌氧玻璃管中,于37℃恒温静置培养活化,活化2次。取活化后的乳双歧杆菌J605菌液200μL离心,收集菌体,分别加入1mL的pH2.5的模拟人工胃液和pH8.0的模拟人工肠液充分混匀,37℃条件下消化3.0h,取样检测活菌数,计算存活率,结果见表1。其中,人工胃液和人工肠液现配现用,短时间内置于4℃冷藏待用。存活率%=活化菌液活菌数/消化后活菌数×100%。
人工胃液配方:配制0.85%生理盐水,稀盐酸调节pH值至2.5,然后加入0.3%胃蛋白酶,充分溶解后用0.22μm微孔滤膜过滤除菌备用。
人工肠液配方:配制0.85%生理盐水,氢氧化钠调节pH值至8.0,然后加入0.1%胰蛋白酶,充分溶解后用0.22μm微孔滤膜过滤除菌备用。
表1 乳双歧杆菌J605模拟消化道环境实验数据表
表1结果显示,乳双歧杆菌J605在模拟人工胃液和人工肠液中存活率均较强,说明该菌能有效抵抗胃肠道的影响,能够在通过胃肠道后仍然有很高的活性。
实验例4、乳双歧杆菌J605的抑菌活性评价
取测试菌液100μL接种于装有7mL MRS液体培养基的充氮厌氧玻璃管中,于37℃恒温静置培养活化。将病原指示菌株大肠杆菌、金黄色葡萄球菌、伤寒沙门氏菌100μL分别接种于10mL液体LB培养基中,于37℃恒温摇床100rpm培养活化。将活化后的病原菌菌液稀释至浓度为108CFU/mL的菌悬液,分别取300μL各病原菌菌悬液添加至30mL适宜温度(50℃左右)的MRS固体培养基中混匀(指示菌活菌数106CFU/mL),倒入提前在平板中放置4个无菌牛津杯的平板中,待培养基凝固后,用镊子取出牛津杯,在牛津杯拔后留下的孔内加入160μL的测试菌菌液(活菌数为108CFU/mL),3个平行,1个对照,其中对照用MRS液体培养基替代。将平皿轻盖后正置,置换空气为无氧空气后,于37℃恒温培养箱培养适宜时间观察,并用游标卡尺测量抑菌圈直径,结果见表2。
LB培养基:胰蛋白胨10g,酵母浸粉5g,氯化钠10g,蒸馏水1000ml,pH7.0~7.2,118℃,15min灭菌。
表2 乳双歧杆菌J605对病原菌的拮抗能力数据表
表2结果显示乳双歧杆菌J605对常见肠道致病菌大肠杆菌、金黄色葡萄球菌和伤寒沙门氏菌均具有很强的抑制作用。
实验例5乳双歧杆菌J605的表面疏水性测定
取测试菌液100μL接种于装有7mL MRS液体培养基的充氮厌氧玻璃管中,重复接3支,37℃恒温培养活化,取菌液离心、去上清,收集菌体,用PBS缓冲液清洗细胞2次后,用PBS重悬,充分振荡打散细胞,调整菌体浓度为OD600约1.0。取15mL菌液至试管,加入5mL二甲苯,以不加二甲苯的菌液为对照,充分振荡混匀,静置20min后,出现分层,取下层水相,测定OD600,计算菌株疏水力。其中疏水能力(%)=(1-At/A0)×100%,,其中At为菌液与二甲苯混匀后水相OD600值,A0为菌液初始OD600值。测定结果见表3。
表3 乳双歧杆菌J605表面疏水能力测试
表3结果显示,乳双歧杆菌菌体经二甲苯处理前后的OD600值分别为0.626和0.093,菌株对二甲苯的疏水力为85.2%。表明乳双歧杆菌J605在肠黏膜表面具有较强的黏附性,有助于菌株在肠道内更好的发挥益生功效。
实验例6、乳双歧杆菌J605的抗生素敏感性评价
将测试菌在MRS固体平板上划线活化后,挑取菌泥于生理盐水中制备菌悬液并调整菌悬液浓度为108CFU/mL,取100μL菌悬液加到提前倒好的MRS固体平板上,用无菌棉签将菌液均匀涂布在平板上,贴上抗生素药敏片,置换空气为无氧空气后37℃正置培养,24h后用游标卡尺测量菌株对抗生素敏感性直径,结果见表4。
表4 乳双歧杆菌J605对抗生素敏感性数据表
表4结果显示,乳双歧杆菌J605对17种常见抗生素均不具有耐药性,证明乳双歧杆菌在应用过程中是安全的。
实验例7、乳双歧杆菌J605的溶血性试验
将保存在冰箱的待测菌株以及对照菌株Bb-12取出接种于装有7mL MRS液体培养基的充氮厌氧玻璃管中,37℃恒温过夜培养,指示菌株金黄色葡萄球菌接种于LB液体培养基中,37℃活化二代后,穿刺(或划线)接种于哥伦比亚血琼脂培养基,37℃静置培养24-48h,观察是否有溶血圈出现,以金黄色葡萄球菌作为指示菌株,判断待测菌株是否具有溶血性。其中溶血性分为3种,α-溶血(菌落周围出现绿色圈),β-溶血(菌落周围的清晰区域),γ-溶血(哥伦比亚血琼脂平板上菌落周围没有圈),菌株表现出γ-溶血显示该菌株是安全的。结果显示,对照菌株金黄色葡萄球菌接种于哥伦比亚琼脂平板培养后菌落周围出现透明的溶血圈,是乙型溶血(β-溶血);而乳双歧杆菌接种于该培养基后,菌落周围未出现溶血圈,因此判断该菌株没有溶血性,不会产生溶血性危害。
实验例8、乳双歧杆菌J605对肠道菌群的调节情况
动物实验分组设计:BALB/c雄性小鼠24只,7周,体重20g/只。小鼠自由饮水、采食,每3h换一次垫料,一周的适应期后进行正式实验。小鼠随机分成3组,每组8只,分别为对照组(NC)、模型组(MC)和给药组(LR)。对照组小鼠实验期间灌胃0.2mL/kg·d生理盐水。模型组、给药组小鼠采用头孢曲松钠生理盐水溶液(浓度125mg/mL)连续灌胃一周(0.2mL/kg·d)以建立菌群失调模型。造模成功后,给药组8只小鼠采用乳双歧杆菌J605菌液灌胃给药15d(2.5×1010CFU/mL,0.2mL/kg·d)。之后三组小鼠统一处死并进行解剖。
其中,实验期间定时监测记录小鼠的体重、摄食量、饮水量等数据。小鼠处死前,取各组小鼠新鲜粪便样品,采用不同的培养基选择性培养检测样品中双歧杆菌属、乳酸杆菌属及其他益生菌的数量,结果见表5。
表5 不同处理组微生物丰度
实验结果显示,正常组原有少量双歧杆菌属、乳酸杆菌属微生物,在菌群失调模型中,该属微生物丰度显著下降,经给药乳双歧杆菌J605,丰度显著回升。该结果有效证明了乳双歧杆菌J605具有良好的促进有益菌的增殖、调节肠道菌群、改善肠内环境的作用。
SEQUENCE LISTING
<110> 湖北均瑶大健康饮品股份有限公司
<120> 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用
<130> P210037/JYD
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> 上游引物27F
<400> 1
agtttgatcm tggctcag 18
<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> 下游引物1492R
<400> 2
ggttaccttg ttacgactt 19
Claims (10)
1.一种乳双歧杆菌Bifidobacterium lactis菌株J605,其特征在于,其保藏号为CGMCCNo.21751。
2.保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605在制备药物或食品方面的应用。
3.根据权利要求2所述的应用,其特征在于,所述药物选自防治消化道病症的药物,优选防治肠道疾病的药物;
优选地,所述食品选自可改善肠道环境的保健食品;
优选地,所述药物的剂型选自:口服液、片剂、粉剂、颗粒剂、胶囊剂、灌肠剂、灌胃剂;
优选地,所述保健食品选自:饮品、含片、固体饮料、咀嚼片、胶囊、颗粒剂和滴剂。
4.一种防治消化道病症的药物,其特征在于,包括药效活性成分;所述药效活性成分包括保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605。
5.根据权利要求4所述的一种防治消化道病症的药物,其特征在于,所述药效活性成分还包括其它常规益生菌;所述其它常规益生菌选自:屎肠球菌、双歧杆菌、粪肠球菌、乳酸杆菌,芽孢杆菌、酪酸梭菌。
6.根据权利要求4或5所述的一种防治消化道病症的药物,其特征在于,还包括药学上可接受的辅料;
优选地,所述药学上可接受的辅料选自:溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、吸收剂、稀释剂、絮凝剂与反絮凝剂、助滤剂、释放阻滞剂。
7.根据权利要求4-6任一所述的一种防治消化道病症的药物,其特征在于,药物剂型选自:口服液、片剂、粉剂、颗粒剂、胶囊剂、灌肠剂、灌胃剂;
优选地,所述药物还包括菌的培养基;所述菌的培养基选自:维生素、乳糖、甘露醇、烟酰胺、乳酸钙、氧化锌、蛋白质、淀粉、水;
优选地,所述防治消化道病症指防治肠道疾病;更优选地,所述防治肠道疾病包括:防治腹泻、便秘、肠炎、肠道菌群失调、肠道消化功能障碍、肠易激综合征。
8.一种保健食品,其特征在于,包括保健活性成分;所述保健活性成分包括保藏号为CGMCC No.21751的乳双歧杆菌Bifidobacterium lactis菌株J605。
9.根据权利要求8所述的一种保健食品,其特征在于,其保健活性成分还包括其它益生菌;所述其它益生菌选自:酵母菌、益生芽孢菌、丁酸梭菌、乳酸杆菌、双歧杆菌、放线菌;
优选地,所述保健食品还包括食品添加剂;
优选地,所述食品添加剂选自:酸度调节剂、抗结剂、消泡剂、抗氧化剂、漂白剂、膨松剂、着色剂、护色剂、酶制剂、增味剂、营养强化剂、防腐剂、甜味剂、增稠剂、香料。
10.根据权利要求8或9所述的一种保健食品,其特征在于,所述保健食品选自:饮品、含片、咀嚼片、固体饮料、胶囊、颗粒剂和滴剂;
所述保健指肠道保健;所述肠道保健指:改善肠道环境、调节肠道菌群。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110362172.3A CN113088465B (zh) | 2021-04-02 | 2021-04-02 | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110362172.3A CN113088465B (zh) | 2021-04-02 | 2021-04-02 | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113088465A true CN113088465A (zh) | 2021-07-09 |
CN113088465B CN113088465B (zh) | 2022-03-22 |
Family
ID=76673427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110362172.3A Active CN113088465B (zh) | 2021-04-02 | 2021-04-02 | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113088465B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110893193A (zh) * | 2019-06-27 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN113564078A (zh) * | 2021-07-29 | 2021-10-29 | 微康益生菌(苏州)股份有限公司 | 一株降胆固醇的乳双歧杆菌BLa80及其应用 |
CN113862181A (zh) * | 2021-09-18 | 2021-12-31 | 河北一然生物科技股份有限公司 | 一种具有肠道调节功能的乳双歧杆菌株rk-7782及其应用 |
CN113913322A (zh) * | 2021-08-25 | 2022-01-11 | 微康益生菌(苏州)股份有限公司 | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 |
CN113969253A (zh) * | 2021-12-07 | 2022-01-25 | 山东中科嘉亿生物工程有限公司 | 一株具有便秘治疗效果的乳双歧杆菌jybr-390及其应用和产品 |
CN114381390A (zh) * | 2021-12-20 | 2022-04-22 | 美益添生物医药(武汉)有限公司 | 长双歧杆菌me-875及其应用 |
CN114480229A (zh) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
CN114717132A (zh) * | 2021-09-08 | 2022-07-08 | 青岛蔚蓝生物股份有限公司 | 一株具有预防和缓解便秘症状的乳双歧杆菌及其应用 |
CN115505543A (zh) * | 2022-09-28 | 2022-12-23 | 天津小薇生物科技有限公司 | 一株乳双歧杆菌br001及其发酵方法与改善过敏的应用 |
CN115747121A (zh) * | 2022-12-12 | 2023-03-07 | 威凯海思(山东)生物工程有限公司 | 一种乳双歧杆菌hsla-009、菌剂及其制备方法和应用 |
WO2023098540A1 (zh) * | 2021-11-30 | 2023-06-08 | 内蒙古伊利实业集团股份有限公司 | 婴儿双歧杆菌ylgb-1496在抗衰老、提高先天免疫方面的新应用 |
CN117736943A (zh) * | 2024-02-20 | 2024-03-22 | 山东中科嘉亿生物工程有限公司 | 一种改善肠易激综合征的复合菌剂及其制备方法和用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018024440A1 (en) * | 2016-08-04 | 2018-02-08 | Nestec Sa | Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rotavirus-associated diarrhoea |
CN110317761A (zh) * | 2019-07-23 | 2019-10-11 | 广东益可维健康科技有限公司 | 一种乳双歧杆菌及其应用 |
CN110892935A (zh) * | 2019-11-15 | 2020-03-20 | 北京科拓恒通生物技术股份有限公司 | 一株用于治疗便秘和腹泻的乳双歧杆菌及其应用 |
CN110893193A (zh) * | 2019-06-27 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN110959676A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌的发酵乳制品及其应用 |
CN111493261A (zh) * | 2020-06-03 | 2020-08-07 | 金华银河生物科技有限公司 | 一种缓解或治疗便秘症状的益生菌固体饮料 |
CN111575214A (zh) * | 2020-06-02 | 2020-08-25 | 北京科拓恒通生物技术股份有限公司 | 一株具有抗幽门螺杆菌功能的乳双歧杆菌及其应用 |
CN112515170A (zh) * | 2019-11-29 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | 提高胃肠道免疫能力的乳双歧杆菌与益生元组合物及应用 |
-
2021
- 2021-04-02 CN CN202110362172.3A patent/CN113088465B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018024440A1 (en) * | 2016-08-04 | 2018-02-08 | Nestec Sa | Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rotavirus-associated diarrhoea |
CN110959676A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种含乳双歧杆菌的发酵乳制品及其应用 |
CN110893193A (zh) * | 2019-06-27 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN110317761A (zh) * | 2019-07-23 | 2019-10-11 | 广东益可维健康科技有限公司 | 一种乳双歧杆菌及其应用 |
CN110892935A (zh) * | 2019-11-15 | 2020-03-20 | 北京科拓恒通生物技术股份有限公司 | 一株用于治疗便秘和腹泻的乳双歧杆菌及其应用 |
CN112515170A (zh) * | 2019-11-29 | 2021-03-19 | 内蒙古伊利实业集团股份有限公司 | 提高胃肠道免疫能力的乳双歧杆菌与益生元组合物及应用 |
CN111575214A (zh) * | 2020-06-02 | 2020-08-25 | 北京科拓恒通生物技术股份有限公司 | 一株具有抗幽门螺杆菌功能的乳双歧杆菌及其应用 |
CN111493261A (zh) * | 2020-06-03 | 2020-08-07 | 金华银河生物科技有限公司 | 一种缓解或治疗便秘症状的益生菌固体饮料 |
Non-Patent Citations (1)
Title |
---|
魏小晶等: "新疆喀什地区维吾尔族婴幼儿肠道双歧杆菌遗传差异及益生特性分析", 《食品科学》 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110893193B (zh) * | 2019-06-27 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN110893193A (zh) * | 2019-06-27 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99的新应用 |
CN113564078A (zh) * | 2021-07-29 | 2021-10-29 | 微康益生菌(苏州)股份有限公司 | 一株降胆固醇的乳双歧杆菌BLa80及其应用 |
CN113564078B (zh) * | 2021-07-29 | 2023-10-20 | 微康益生菌(苏州)股份有限公司 | 一株降胆固醇的乳双歧杆菌BLa80及其应用 |
CN113913322A (zh) * | 2021-08-25 | 2022-01-11 | 微康益生菌(苏州)股份有限公司 | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 |
CN114717132A (zh) * | 2021-09-08 | 2022-07-08 | 青岛蔚蓝生物股份有限公司 | 一株具有预防和缓解便秘症状的乳双歧杆菌及其应用 |
CN114717132B (zh) * | 2021-09-08 | 2023-07-07 | 青岛蔚蓝生物股份有限公司 | 一株具有预防和缓解便秘症状的乳双歧杆菌及其应用 |
CN113862181A (zh) * | 2021-09-18 | 2021-12-31 | 河北一然生物科技股份有限公司 | 一种具有肠道调节功能的乳双歧杆菌株rk-7782及其应用 |
WO2023098540A1 (zh) * | 2021-11-30 | 2023-06-08 | 内蒙古伊利实业集团股份有限公司 | 婴儿双歧杆菌ylgb-1496在抗衰老、提高先天免疫方面的新应用 |
CN113969253A (zh) * | 2021-12-07 | 2022-01-25 | 山东中科嘉亿生物工程有限公司 | 一株具有便秘治疗效果的乳双歧杆菌jybr-390及其应用和产品 |
CN113969253B (zh) * | 2021-12-07 | 2022-07-12 | 山东中科嘉亿生物工程有限公司 | 一株具有便秘治疗效果的乳双歧杆菌jybr-390及其应用和产品 |
CN114381390A (zh) * | 2021-12-20 | 2022-04-22 | 美益添生物医药(武汉)有限公司 | 长双歧杆菌me-875及其应用 |
CN114381390B (zh) * | 2021-12-20 | 2023-11-17 | 美益添生物医药(武汉)有限公司 | 长双歧杆菌me-875及其应用 |
CN114480229B (zh) * | 2022-04-15 | 2022-08-09 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
CN114480229A (zh) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
CN115505543A (zh) * | 2022-09-28 | 2022-12-23 | 天津小薇生物科技有限公司 | 一株乳双歧杆菌br001及其发酵方法与改善过敏的应用 |
CN115505543B (zh) * | 2022-09-28 | 2024-01-26 | 天津小薇生物科技有限公司 | 一株乳双歧杆菌br001及其发酵方法与改善过敏的应用 |
CN115747121A (zh) * | 2022-12-12 | 2023-03-07 | 威凯海思(山东)生物工程有限公司 | 一种乳双歧杆菌hsla-009、菌剂及其制备方法和应用 |
CN117736943A (zh) * | 2024-02-20 | 2024-03-22 | 山东中科嘉亿生物工程有限公司 | 一种改善肠易激综合征的复合菌剂及其制备方法和用途 |
CN117736943B (zh) * | 2024-02-20 | 2024-05-24 | 山东中科嘉亿生物工程有限公司 | 一种改善肠易激综合征的复合菌剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN113088465B (zh) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113088465B (zh) | 一种乳双歧杆菌Bifidobacterium lactis菌株J605及其应用 | |
CN111484957B (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
CN110964655B (zh) | 一种乳双歧杆菌bl-99及其应用 | |
CN112175864B (zh) | 动物双歧杆菌及其选育方法和应用 | |
CN110959865B (zh) | 可调节胃肠道菌群平衡的副干酪乳杆菌k56的新应用 | |
CN110964653B (zh) | 一种可调节肠道菌群平衡的副干酪乳杆菌et-22 | |
CN113913322B (zh) | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 | |
CN113832058A (zh) | 乳双歧杆菌BLa80在制备降血脂和调节肠道菌群的药物或食品中的应用 | |
CN110893193B (zh) | 乳双歧杆菌bl-99的新应用 | |
CN113122466B (zh) | 粪肠球菌及其应用 | |
CN113564078A (zh) | 一株降胆固醇的乳双歧杆菌BLa80及其应用 | |
CN114480231A (zh) | 一种抗幽门螺杆菌感染的罗伊氏乳杆菌及其应用 | |
CN111543640A (zh) | 一种具有改善小儿腹泻和消化不良的动物双歧杆菌乳亚种i797的应用 | |
JP2008054556A (ja) | 免疫賦活作用及び/又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌 | |
Utami et al. | Recovery of Lactobacillus Casei Strain Shirota (Lcs) From the intestine of healthy Indonesian volunteers after intake of fermented milk and its impact on the enterobacteriaceae faecal microbiota | |
CN114990030B (zh) | 嗜酸乳杆菌la18及其在制备调节肠道菌群或免疫调节的产品方面的应用 | |
RU2491336C1 (ru) | Консорциум бифидобактерий и лактобацилл, используемый для приготовления бактерийных препаратов и биологически активных добавок, предназначенных для коррекции микрофлоры людей старше 14 лет, способ его получения, биологически активная добавка к пище для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет и бактериальный препарат для лечения дисбиотических состояний желудочно-кишечного тракта людей старше 14 лет | |
TWI792249B (zh) | 使用乳酸菌菌株的發酵培養物來治療和/或預防幽門螺旋桿菌感染的相關疾病 | |
Ouwehand et al. | Production of probiotic bifidobacteria | |
CN114381390A (zh) | 长双歧杆菌me-875及其应用 | |
CN117165497B (zh) | 一种改善便秘的植物乳植杆菌Lp18及其应用和产品 | |
CN117070398B (zh) | 一种改善便秘的动物双歧杆菌乳亚种Bi66及其应用、产品和方法 | |
CN117448243B (zh) | 一株具有益生功能且能增强免疫的嗜粘蛋白阿克曼氏菌Akk007及其应用与保健品 | |
CN117106628B (zh) | 一种具有免疫调节能力的嗜酸乳杆菌la15及其应用、产品与方法 | |
CN114574405B (zh) | 植物乳杆菌菌株wka86及其在制备防治口臭制品方面的用途与制品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |